AstraZeneca (AZN LN) announces positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in the lancet respiratory medicine

AstraZeneca's announcement of positive results from the KALOS and LOGOS trials is significant as it underscores the effectiveness of BREZTRI in treating uncontrolled asthma, which could lead to increased adoption and sales of the drug.

Newsquawk StaffPublished On the live feed at 1 more headline followed before this page went public
Newsquawk headlinesUTC

PRIMER - US January CPI data is due at 13:30GMT/08:30EST

US sending second aircraft carrier group to Middle East, CNN reports

AstraZeneca (AZN LN) announces positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in the lancet respiratory medicine

Ukraine President Zelensky says Ukraine plans to open 10 joint drone production facilities this year; he visited joint Ukrainian-German drone production

Moderna Inc. (MRNA) Q4 2025 (USD): EPS -2.11 (exp. -2.54), Revenue 700mln (exp. 635mln)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This could also enhance investor confidence in AstraZeneca's pipeline, potentially contributing to stronger equity performance within the pharmaceuticals sector. Keep an eye on how this news impacts AstraZeneca's stock and the broader pharmaceutical market sentiment.

Related headlines

The whole workspace, free to try.

Try it free